{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:09:06Z","timestamp":1777428546435,"version":"3.51.4"},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T00:00:00Z","timestamp":1398211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,8]]},"abstract":"Summary<\/jats:title>National antenatal screening of all pregnant women in E<\/jats:styled-content>ngland is carried out using standards and guidelines produced by the National Health Service Sickle Cell and Thalassaemia Screening Programme. The algorithms for detection of beta thalassaemia carrier status rely on action criteria, which are set using the percentage Hb A2<\/jats:sub> and mean corpuscular haemoglobin (MCH<\/jats:styled-content>) values. Three groups of samples: MCH<\/jats:styled-content> <27\u00a0pg and Hb A2<\/jats:sub> 3\u00b75\u20133\u00b79%, MCH<\/jats:styled-content> \u226527\u00a0pg and Hb A2<\/jats:sub> 4\u20134\u00b73% and MCH<\/jats:styled-content> \u226527\u00a0pg and Hb A2<\/jats:sub> 3\u00b75\u20133\u00b79% were selected from a sample population of 59\u00a0500 to assess the validity and predictive value of the action criteria \u2013 25 false positives (0\u00b7042% of total) and nine false negatives (0\u00b7015% of total) were detected. These findings support the continuation of the current action values.<\/jats:p>","DOI":"10.1111\/bjh.12917","type":"journal-article","created":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T09:20:49Z","timestamp":1398244849000},"page":"607-611","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of the validity of Hb A2<\/sub> and mean corpuscular haemoglobin action values in antenatal screening for beta thalassaemia carriers in E<\/scp>ngland"],"prefix":"10.1111","volume":"166","author":[{"given":"Yvonne","family":"Daniel","sequence":"first","affiliation":[{"name":"Red Cell Centre Special Haematology, Guys & St Thomas Hospital GSTS Pathology London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronwyn","family":"Cartwright","sequence":"additional","affiliation":[{"name":"Haematology Department Guys & St Thomas Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Rennie","sequence":"additional","affiliation":[{"name":"Haemoglobinopathy Genetics University College London Hospitals London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Streetly","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Public Health Sciences Kings College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Howard","sequence":"additional","affiliation":[{"name":"Haematology Department Guys & St Thomas Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,23]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"Evaluation of UK NEQAS (H) HbA2 and Related Performance Data","author":"Batterbee H.","year":"2010"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0223(199901)19:1<58::AID-PD453>3.0.CO;2-1"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/03630260902827684"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1258\/jms.2012.012083"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta8200"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.014704"},{"key":"e_1_2_7_8_1","unstructured":"NHS Sickle Cell & Thalassaemia Screening Programme(2012)Handbook for Laboratories 3rd edn. Available at:http:\/\/sct.screening.nhs.uk\/getdata.php?id=10756(accessed November 19 2013)."},{"key":"e_1_2_7_9_1","unstructured":"NHS Sickle Cell & Thalassaemia Screening Programme(2013)Data Report 2011\/12 Trends and perfomance analysis. Available at:http:\/\/sct.screening.nhs.uk\/getdata.php?id=12725(accessed March 11 2014)."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-345736"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2011.01368.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12917","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T21:48:47Z","timestamp":1696283327000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,23]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/bjh.12917"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12917","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,23]]},"assertion":[{"value":"2014-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}